Abstract: This invention relates to novel (+)-5-isopropyl 3-methyl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate.More particularly, it relates to novel (+)-5-isopropyl 3-methyl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate, which has pharmacological activities such as hypotensive and vasodilating activities, to a pharmaceutical composition comprising the same and to a method for treating hypertension, cardiovascular diseases, and the like.Accordingly, one object of this invention is to provide novel (+)-5-isopropyl 3-methyl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate, which is of use for treating hyperxtension, cardiovascular diseases, and the like.

Abstract: This invention relates to new ethanolamine derivatives having gut selective sympathomimetic and anti-pollakiuria activities and represented by the general formula [I]: ##STR1## wherein R.sup.1 is aryl or a heterocyclic group, each of which may be substituted with halogen, etc.,R.sup.2 is hydrogen, halogen, nitro, hydroxy, lower alkyl optionally substituted with acyl, lower alkenyl optionally substituted with acyl, lower alkoxy optionally substituted with acyl, or amino optionally substituted with acyl(lower)alkyl,R.sup.3 is hydrogen, an N-protective group, or lower alkyl optionally substituted with lower alkylthio,n is an integer of 0 to 3, anda heavy solid line means a single bond or a double bond,provided that when n is 1, then1) R.sup.1 is a condensed aromatic hydrocarbon group or a heterocyclic group, each of which may be substituted with halogen, etc.

Abstract: The present method for the treatment of pancreatitis, which comprises administering an effective amount of a pyrazolopyridine compound of the following formula: ##STR1## wherein R.sup.1 is lower alkyl, (substituted) aryl, or a heterocyclic group,R.sup.2 is a group of the formula ##STR2## wherein R.sup.4 is protected amino or hydroxy and R.sup.5 is hydrogen or lower alkyl; cyano; a group of the formula --A--R.sup.6, wherein R.sup.6 is an acyl group, and A is (halogenated) lower aliphatic hydrocarbon group; amidated carboxy; an unsaturated heterocyclic group; or (protected) amino; andR.sup.3 is hydrogen, lower alkyl, lower alkoxy or halogen; or a pharmaceutically acceptable salt thereof, to a human being having pancreatitis or an animal having pancreatitis in need thereof.

Abstract: The disclosure concerns pyrazolopyridine compounds of the formulawherein the variables are defined in the specification. The compounds are useful as a diuretic, anti-hypertensive agent, etc.

Abstract: The compound (-)-N-t-butyl-4,4-diphenyl-2-cyclopentenylamine, or its hydrochloride salt has anticholinergic activity, and thus has a variety of pharmaceutical utilities.

Abstract: This invention relates to pyrazolopyridine compounds for the treatment of melancholia, heart failure, hypertension, renal insufficiency, renal toxicity, nephrosis, nephritis, edema, obesity, bronchial asthma, gout, hyperuricemia, sudden infant death syndrome, immunosuppression, diabetes, myocardial infarction, thrombosis, obstruction, arteriosclerosis obliterans, thrombophlebitis, cerebral infarction, transient ischemic attack or angina pectoris, said compounds being of the formula ##STR1## wherein the radicals are defined in the claims.

Abstract: There are disclosed 3 [2(substituted alkyl)-3-oxo-2,3-dihydropyridazin-6-yl]-2-aryl pyrazolo [1,5-a]-pyridines useful for treating maladies requiring an adenosine antagonist, and preparative processes.

Abstract: Compounds of the formula ##STR1## wherein R.sup.1 is aryl which may have one or more suitable substituent(s)R.sup.2 is aryl which may have one or more suitable substituent(s), lower alkyl or cyclo(lower)alkyl,R.sup.3 is hydrogen, hydroxy, halogen, lower alkenyl, amino or protected amino,R.sup.4 is a group of the formula: ##STR2## wherein R.sup.5 is lower alkyl which may have one or more suitable substituent(s), cyclo(lower)alkyl, aryl, ar(lower)alkyl which may have one or more suitable substituent(s), andR.sup.6 is hydrogen or lower alkyl; or N-containing heterocyclic group which may have one or more suitable substituent(s), andA is lower alkylene or lower alkynylene, in which R.sup.1 and R.sup.2 may be linked through an oxygen atom, their preparation and use in treatment of dysuria, and starting materials for their preparation.

Abstract: The disclosure deals with pyrazolopyridine compounds of the formula: ##STR1## wherein the variables are defined in the specification. The compounds are useful as a diuretic, anti-hypertensive agent, etc.

Abstract: The invention relates to a method for the prevention and/or treatment of renal toxicity, nephrosis or nephritis, which comprises administering a pyrazolopyridine compound of the formula: ##STR1## wherein R.sup.1 is aryl, andR.sup.2 is unsaturated heterocyclic group which contains at least one heteroatom selected from the group consisting of N, O and S, which may have one or more suitable substituent(s), or a pharmaceutically acceptable salt thereof to a human being or an animal.

Abstract: Benzopyrene derivatives effective for the treatment of hypertension have been prepared.

Abstract: The invention relates to a method for the treatment of renal toxicity, nephrosis or nephritis which comprises administering an effective amount of the pyrazolopyridine compounds of the invention.

Abstract: The invention relates to a method for the treatment of ailments which comprises administering an effective amount of the pyrazolopyridine compounds of the invention.

Abstract: The invention relates to novel pyrazolopyridine compounds useful as a diuretic, antihypertensive agaent, for renal insufficiency, for thrombosis, and as a cardiotonic agent.

Abstract: Compounds of the formula ##STR1## wherein R.sup.1 is aryl which may have one or more suitable substituent(s),R.sup.2 is aryl which may have one or more suitable substituent(s), lower alkyl or cyclo(lower)alkyl,R.sup.3 is hydrogen, hydroxy, halogen, lower alkenyl, amino or protected amino,R.sup.4 is a group of the formula: ##STR2## wherein R.sup.5 is lower alkyl which may have one or more suitable substituent(s), cyclo(lower)alkyl, aryl, ar(lower)alkyl which may have one or more suitable substituent(s), andR.sup.6 is hydrogen or lower alkyl; or N-containing heterocyclic group which may have one or more suitable substituent(s), andA is lower alkylene or lower alkynylene, in which R.sup.1 and R.sup.2 may be linked through oxygen atom, their preparation and use in treatment of dysuria, and starting materials for their preparation.

Abstract: The invention relates to a nitric ester derivative with vasodilating properties for treatment of cardiovascular disorders, the derivative being of the formula ##STR1## wherein R.sup.1 is hydrogen, lower alkyl, halo(lower)alkyl, halogen, phenyl, nitrophenyl, pyridyl, morpholino, piperidino, amino, lower alkanoylamino, higher alkanoylamino, benzamido, lower alkoxycarbonylamino, N-lower alkylamino, N,N-di(lower)alkylamino, N-lower alkyl-N-lower alkanoylamino, 3-lower alkylureido or N,N-di(lower) alkylamino(lower)alkyl,R.sup.2 is hydrogen, lower alkyl or N-(nitrooxy(lower)alkyl)carbamoyl,Y is a single bond, lower alkylene or lower alkenylene, andZ is ethylene, trimethylene, tetramethylene, 1-methylnitrooxymethylethylene, 1,1-bis(nitrooxy-methyl)ethylene, 2-nitrooxytrimethylene or ethyleneoxyethylene, and pharmaceutically acceptable salts thereof.

Abstract: The disclosure deals with pyrazolopyridine compounds of the formula ##STR1## wherein the variables are defined in the specification. The compounds are useful in the treatment of bronchial asthma, immunosuppression, diabetes, etc.

Abstract: Benzopyran derivatives of formula (I) wherein the substituents are as defined herein are provided. The compounds possess vasodilating activity and are useful in the treatment of hypertension. Pharmaceutical compositions and methods of treating hypertension are also provided.

Abstract: The invention relates to pyrazolopyridine compounds for the treatment of melancholia, heart failure, hypertension, renal insufficiency, edema, obesity, bronchial asthma, gout, hyperuricemia, sudden infant death syndrome, immunosuppression, diabetes, myocardiac infection, thrombosis, obstruction, arteriosclerosis obliterans, thrombophlebitis, cerebral infarction, transient ischemic attack or angina pectoris, said compounds being of the formula ##STR1## wherein R.sup.1 is aryl, andR.sup.2 is unsaturated heterocyclic group which contains at least one heteroatom selected from the group consisting of N, O and S, which may have one or more suitable substituent(s),or a pharmaceutically acceptable salt thereof.

Abstract: The disclosure deals with a pyrazolopyridine compound of the formula ##STR1## wherein the variables are defined in the specification. The compounds are useful as a diuretic, antihypertensive agent, etc.